Global Women's Health Market is anticipated to grow at a decent CAGR of over 4.5% to reach $47 billion by 2026 - LUPIN, Bayer AG, AstraZeneca, Novartis AG, Mithra, Allergan, AbbVie, Eli Lilly, Pfizer, Merck & Co., Ferring

Women's Health is a branch of healthcare and medicine which focuses on the prevention and diagnosis of diseases which affect a woman's physical and emotional well-being. It encompasses a vast variety of medical treatments, drugs, and surgical products for diseases related to women's health.

Upcoming Growth Opportunities in Women's Health Market

The growing prevalence of infectious and chronic diseases among a large female population is a primary factor which is driving the growth of the women's health market. Recent technological advancements in genomics, tissue engineering, artificial intelligence, and cell and gene therapy have synergized a new wave of healthcare innovations which can be applied to create products and solutions pertaining to women's health conditions.

The global women's health market is driven by the rising occurrence of women-centric diseases (such as endometriosis, osteoporosis, breast cancer, menopause), the introduction of innovative products for women's health, government initiatives to curb the population growth, and an increasing demand for contraceptives to avoid unwanted pregnancies.

Market Challenges: Global Women's Health Market

The high costs associated with the clinical care in few countries and side effects associated with the utilization of women's health drugs (such as night sweats, headache, nausea, and difficulty sleeping) is likely to restrain the global growth of the women's health market.

Geographic Overview: North America is the Largest Women's Health Market

North America has the largest share of the women's health market, followed by Europe and Asia-Pacific. The large share of North America can be attributed to the healthy economies of United States and Canada, established reimbursement policies, early approval and commercialization of products and the presence of established market players in this regions. Asia-Pacific holds a minor share in the global women's health market.

Competitive Landscape Analysis: Global Women's Health Market
Some of the established and promising players operating in this market are AbbVie Inc, Eli Lilly, Pfizer Inc., Merck & Co., Ferring Pharmaceuticals, LUPIN, Bayer AG, AstraZeneca, Novartis AG, Mithra Pharmaceuticals, Allergan.

Market Trends: Global Women's Health Market

The women's health market is a quite consistent but competitive market marked by the presence of both established and new players. Players operating in this market have adopted both organic and inorganic growth strategies such as collaborations and acquisitions to garner higher market share. For instance,

• In March 2022, Carlyle Group and PAI Partners announced the acquisition of women's health business Theramex from private equity firm CVC Capital Partners.
• In November 2021, Organon announced the acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments for women's health.

The growth prospects of the women's health market looks quite promising considering the strategic collaborations & acquisitions, favorable regulatory landscape, and growth in investments from private equity firms, venture capitalists, and government globally, new product launches, and advancements in R&D to build a robust product pipeline by market players.

Get a Detailed & Customized Report on Women's Health Market @ https://meditechinsights.com/global-womens-health-market/

Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.